Neurology

Statins can benefit patients with secondary progressive multiple sclerosis for reasons unrelated to their cholesterol-lowering effects.

New data show that higher exposure to ocrelizumab (Ocrevus, Genentech) correlated with lower B-cell levels and lower rates of disability progression.

Compared with interferon beta-1a, ozanimod reduced less cortical grey matter volume in patients with relapsing forms of multiple sclerosis.

An investigational therapy for amyotrophic lateral sclerosis has shown promise in slowing the progression of the disease in patients with a genetic form of the disease.

There is no cure for multiple sclerosis, but there are more than a dozen treatment options that aid in reducing the severity of the disease.

In the first and largest study of its kind, researchers from the University of British Columbia (UBC) and Vancouver Coastal Health Research Institute aimed to assess mortality associated with beta interferons for the treatment of MS.

The study authors believe that the modification of teriflunomide and the development of new DHODH inhibitors is urgent for drug-resistant epilepsy patients

Patients taking beta interferons for at least 6 months had a reduced mortality risk compared with patients who did not take the drug.

The study authors believe that the modification of teriflunomide and the development of new DHODH inhibitors is urgent for drug-resistant epilepsy patients

Sobetirome was shown to stimulate myelination in mice without the severe adverse effects commonly associated with thyroid hormone therapy for multiple sclerosis.

Approximately 1 in 5 patients in a study were misdiagnosed with multiple sclerosis before being referred to treatment centers.

Brain stem cells of patients with primary progressive multiple sclerosis appear to age faster.

Cladribine (Mavenclad, EMD Serono) is the first oral multiple sclerosis drug to demonstrate 2 years of proven efficacy with a maximum of 20 days of treatment.

Cladribine (Mavenclad, EMD Serono) is the first oral multiple sclerosis drug to demonstrate 2 years of proven efficacy with a maximum of 20 days of treatment.

Top news of the week from Specialty Pharmacy Times.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Novartis’ siponimod (Mayzent) is approved for adults with active secondary progressive multiple sclerosis, clinically isolated syndrome, and relapsing-remitting disease.

Study is the first and largest of its kind to examine mortality associated with beta interferons, the first drugs to be approved for the treatment of relapsing-onset multiple sclerosis.

Patients with multiple sclerosis who consumed 2 cans of soda per day were 5 times more likely to experience severe disability.

Higher body mass index at beginning of menstruation linked to greater risk of developing multiple sclerosis.

A recent study showed that flavonoid-rich cocoa improved fatigue by 45% in patients with relapsing and remitting multiple sclerosis.

Women with multiple sclerosis who breastfed exclusively for at least 2 months had a 40% lower rate of relapse compared with women who did not breastfeed.

Stem cell transplantation found to provide greater protection than disease-modifying therapy against progression of relapsing-remitting multiple sclerosis.

Study focuses on the importance of distinguishing whether sugar-sweetened beverages heightened disability in patients with multiple sclerosis.